for precision medicine版精准医疗的价值和影响

Genetherapy“Kill

Cell “Thetailoringofmedicaltreatmenttotheindividualcharacteristicsofeachpatient…toclassifyindividualsintosubpopulationsthatdifferintheirsusceptibilitytoaparticulardiseaseortheirresponsetoaspecifictreatment.Preventativeortherapeuticinterventionscanthenbeconcentratedonthosewhowillbenefit,sparingexpenseandsideeffectsforthosewhowillnot”

现代诊断筛查特定人群患某种疾病的风险,以及对某种药物的疗效和毒副作用的差异化反应。从而达到“正确的，在、药物

液体活检(CTCscfDNAet

“On“Ondrugfitsall”and“Errorand“Precise “大适应症”模式(市场大,成功率低)转向“精确制导” Humira和

Sovaldi和“免疫疗法”治人，通过纠

适应症 适应症适应症 适应症

提高疗效：Imatinib抑制Bcr-Ab

(FDA,“pavetheway alizedmedicine”,

%((IMSreport, AdaptiveandEnrichedBasketUmbrellaClusterPfizer’sCrizotinibAZ’sAZD9291

镇痛升白

2%

CNS

20152015Aby6$1502214202010201120122013(AdaptedfromThomson, Crizotinib克唑替尼Icotinib埃克替尼Pazopanib帕唑帕尼Nilotinib尼洛替尼Ponatinib普纳替尼Radotinib拉多替尼Dabrafenib达拉菲尼Trametinib曲美替尼MasitinibAZD9291Volasertib；itinib；BaricitinibCobimetinib；PlitidepsinFedratinib；FostamatinibNeratinib；NeratinibBuparlisib;CS-055C-9544342GLP-856644333BeattolterodineHypothesisM2leadingtosideeffectHypothesis-driven适合创新性企业需要提出和验证假说的能

Icotinib molecularcancertherapeutics2015,14,2187EmilyWhitehead ScientificScientificbreakthroughLeadstorenaissanceofimmunotherapyapproachestousethebody’sownimmunesystemtofightcancer, andbrainaggregatesFirstcellularimmunotherapyApprovedforbladdercancer(Provenge)Anti-CTLA4mAbApprovedformelanoma

Approvedformelanoma(Opdevo&Keytruda)Opdevo&Keytruda

US“moon Anti-PD-L1mAbregisteredNumerousnewIOtherapiesinclinicaldevelopmentCARTpromisingincancerImmunotherapiesexpandanti-(clinical

ImmunotherapyandcombinationdrugswillbeagoldminefordisruptiveblockbustersfordecadestocomeparticularlyinoncologyinfectiousandCNS

Approvedfor

NK

PD-DrugmAbsandFusion

DrugmAbsandFusion

DrugmAbsandFusioncell

CSF1DrugmAbsandFusioncell

OthersolubleDrugmAbsandFusionCell

药

(SeminarsinImmunology,Novartis;U20MbyUCelgene;GSK;NY-ESO-1targetingAmgen;Celgene;CART 的问ReceptorintroductionLongexvivoexpansionCytokinestormHomingWeakactivitiesLimitationforsolid

“cellsqueeze”(SQZ);CRSPR-CasCytokineselection(IL-2,IL-15,etIdentificationof“younger”long-lastingsub-populationofTcellsOff-the-shelfCART(NK),Cell- CART-derivedexosomeIntroductionofchemokinereceptor,stroma-eatingCART(FAP)Combinationofmultiple s(2ndand3rdgenCART);combinationwithcytokines,checkpointinhibitororco-stimulationagonist;KIR-knockoutNK(aNK);highaffinityNK(haNK),targetingNK( Label-targetingCART,homing ,multipleneo intracellularantigen-targeting;

魏Zinc切酶;只需设计指的ssDNA剪切酶点分开,难以编辑;因此 编辑技术:NatureBiotechnology,2016,online,may“DNA-guidedgenomeeditingusingtheNatronobacteriumgregoryi(moleculartherapy,2016,(moleculartherapy,2016,(moleculartherapy,2016,发展最快 编辑技 纷作物;同时技术;HIV华Doudna实验

TBloodBloodWhat

TreatornotGeneGeneWhatWhatLifeMyriad

T

报告 成本已降至成本已降至的 报告 吴一龙教授透露，目 报告 NAVgenetherapy;RGX-501HoFH;RGX-111MPSI;RGX-121II;RGX-314wetAMD;RGX-321Claritas WuXiNextcode;波士顿儿童医院NGS,microarray,etalforchildrenrarediseases;ClariView 癌相关的19 括BRCA1和BRCA2成本 Singlemoleculedetection;SequencingByXpansion 和预防的方案;250指标;Fitbit可穿戴; B1.2亿/8月 ;BillGates CRISPR-Cas9;TALENs;rarediseasesMetamarkGenetecs liatherapeutics Orbimed;Fidelity CRISPR-Cas923and al Windham;Nanjing 创、微旋、聚道科技、、思博奥科、爱普益医学、迈基诺、奇云诺德、量化健康、诺塞组等 、谱元科 达安、拓普、锐博生物、燃石生物、永诺生物、库基生物、坤图生物、美格生物、基迪奥生物、瑞科、艾基生物、金域检测、安必平、博奥木华、漫瑞生物

杭州 从投资的角度 的技术,比 DNAnexus, 如果只是拿着投资人的钱,找Illumina买几台先进的 仪,提供

T

循环

CTCs的捕捉技术（CellSearchand新技术：HB-chip;CTC-iChip;GFP;tumor- CTCsctDNAandcfDNA ARMS 扩增阻滞突 0.1- 序 0.01%或更 $60M/B；1.27,Codiak与CTCs相比，外泌体不2016.5.3,Foundation上市ctDNA液体活检

T功能测试与一起将成为精准医疗Nature,2015,基 （CP-可分 ,细菌 Trendsinbiotechnology,2015,

FG预测模型(软件基 的报

华 阿里云BGIGenomics;AmazonWebAppleResearchKit;IBMBluemixTuteGenomics;SevenBridge;WuXiAppTecNextCode(明码云);IlluminaBaseSpace我们得知道某 变异意味着什年 forFastestGenetic 医院：RadyChildren'sHospital-SanDiegoDrStephen：Illumina EdicoGe